Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$368.57 - $678.21
Previous CloseN/A
Volume151.62K
Average Volume (3M)406.25K
Market Cap
$35.15B
Enterprise Value$32.10B
Total Cash (Recent Filing)$3.38B
Total Debt (Recent Filing)$39.05M
Price to Earnings (P/E)41.5
Beta0.49
Next Earnings
Jul 31, 2025EPS Estimate
2.99Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.58
Shares Outstanding61,059,563
10 Day Avg. Volume268,529
30 Day Avg. Volume406,255
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.98
Price to Sales (P/S)0.00
P/FCF Ratio-432.36
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue5.73
Enterprise Value/Gross Profit32.30
Enterprise Value/Ebitda-35.54
Forecast
1Y Price Target
$752.17Price Target Upside30.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Argenx Se News
Bulls Say, Bears Say
Bulls Say
Growth PotentialVyvgart's uptake in gMG and CIDP continues to look strong with new patient additions.
Market ExpansionThe self-administration option could increase uptake in additional patient segments and improve adherence.
Product ApprovalVyvgart Hytrulo pre-filled syringe was approved by the FDA, allowing patients to self-administer without healthcare professional monitoring.
Bears Say
Financial PerformanceThe stock is down due to Q missing buyside expectations and Q1 impact from seasonality and Part D Redesign.
Legislative RisksChanges in language regarding tariffs may require legislative action, which could be difficult to implement, creating uncertainty for ARGX.
Taxation RisksComplexities around changing transfer pricing could lead to a risk of double taxation if not mutually agreed upon by both the IRS and the Belgian government.
Ownership Overview
―
Insiders
14.67% Mutual Funds
20.14% Other Institutional Investors
63.65% Public Companies and Individual Investors
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $368.57 and its highest was $678.21 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $35.15B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is Jul 31, 2025 which is in 55 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on May 08, 2025. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.421 by $0.159.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 2.99.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,059,563 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $2.58 in its last earnings report, beating expectations of $2.421. Following the earnings report the stock price went down -8.638%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$752.17 (30.45% Upside)
$752.17 (30.45% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 39.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 12.1%
Last 30 Days ▲ 12.4%
Last 30 Days ▲ 12.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
52.57%
12-Months-Change
Fundamentals
Return on Equity
17.33%
Trailing 12-Months
Asset Growth
36.55%
Trailing 12-Months
Company Description
Argenx Se
Argenx SE (ARGX) is a global biotechnology company focused on developing therapies targeting autoimmune diseases and cancer. The company leverages its proprietary antibody engineering technology platform to create innovative treatments aimed at improving patient outcomes. Argenx's core products include efgartigimod, a first-in-class FcRn antagonist for the treatment of autoimmune diseases, and a robust pipeline of other therapeutic candidates in various stages of development.
ARGX Company Deck
ARGX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant commercial success with record-breaking revenue growth and successful product launches. The company is in a strong financial position and advancing its pipeline with promising data presentations. However, there were challenges related to seasonality, gross-to-net impacts, and unique market dynamics in CIDP that affected growth. Overall, the sentiment is positive due to the strong growth and strategic advancements outweighing the lowlights.Read More>ARGX Stock 12 Month Forecast
Average Price Target
$752.17
▲(30.45%Upside)